Thales Unveils New Secrets Management Solution to Help Reduce Risks and Improve DevOps and Cloud Security
Thales, the leading global technology and security provider, today announced the introduction of a new secrets management solution as part of its CipherTrust Data Security platform which unifies the discovery, classification, protection, and control of sensitive data across cloud, on-premises and hybrid environments. Thales’s new secrets management solution, powered by Akeyless’ Vault Platform, enables customers to manage and secure DevOps and cloud workloads’ secrets. The new capability enhances the capabilities of the CipherTrust Data Security platform to help security and governance teams reduce risks by streamlining security processes across their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230424005088/en/
@Thales
Thales’ new secrets management solution helps ensure that only authorized workloads and applications can access their passwords, API keys, and certificates, protecting them from unauthorized access, theft, or misuse. The process of secrets management typically involves generating and storing secrets securely, controlling access, and monitoring to alert when there is a suspicion of a breach and associated details.
Todd Moore, vice president of data security products at Thales: "Combining secrets management with key management is like having a fortified vault for all your valuable assets. We are pleased to meet our customers growing business needs by offering a single data security platform that can simplify the management of all their sensitive data, improve security and compliance, foster development collaboration, and scale their security infrastructure."
The addition of secrets management enables the CipherTrust Data Security Platform to solve several pain points for customers related to the storing and managing of secrets securely, including:
- Mitigating the risk of data breaches: By providing secure storage and access control to sensitive data such as passwords, API keys, and certificates, which are valuable targets for attackers, it mitigates the risk of data breaches.
- Simplifying the management of secrets: In many organizations, passwords and certificates are managed manually or with ad-hoc processes, which are time-consuming and error-prone, especially in large or complex environments.
- Ensuring compliance with regulations and standards: Some industries and regions require compliance with specific regulations and standards for data security which could be very complex to navigate.
- Enabling collaboration: Multiple teams or individuals who need access to secrets now have a centralized and secure way to collaborate on projects.
With support for secrets management, the CipherTrust Data Security Platform further simplifies customers' processes by allowing centralized management of secrets and keys and scaling up to encryption solutions and other data security use cases.
Shai Onn, President & Co-founder at Akeyless : “As enterprises increasingly adopt DevOps practices, Automation, containerization, and more cloud technologies, they face a new rising threat in the form of Secrets Sprawl, where credentials, certificates and keys of all forms are being found in large quantities within source code, configuration files, and DevOps automation platforms. In recent years, Akeyless has pioneered the SaaS based Secrets Management market, becoming the perfect choice for reputable enterprises globally, making it a natural partner for Thales. With Akeyless Vault Platform’s secrets management solution, Thales can offer a more holistic and cohesive platform for its customers enabling them to centralize and streamline their DevOps Security efforts, Cloud IAM initiatives and Encryption solutions projects.
For a demo, visit Thales’ booth #N-5369 and Akeyless.io’s booth #S-1861 at RSA 2023 (April 24 – 27 in San Francisco, USA) or learn more here.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005088/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
